The relationship between the administration time and diet of Acalabrutinib needs to be comprehensively considered based on the characteristics of the drug and the individual situation of the patient. Its absorption is less affected by food, but attention should be paid to the timing of administration in specific situations.

1. Conventional administration recommendations

(1) Standard protocol: Oral administration twice a day (approximately 12 hours apart).

(2) Basic principle: It can be taken with food or on an empty stomach, and the administration time should be regular.

(3) Formulation characteristics: Capsule formulation is not affected by gastric acid environment and has good absorption stability.

Analysis of Dietary Effects

(1) High fat diet: may delay peak time but does not affect overall absorption.

(2) Changes in gastric acid: When proton pump inhibitors are used in combination, there is no need to adjust the administration time.

(3) Special diet: CYP3A inhibitors such as grapefruit should be avoided from being taken together.

3 Adjustments for Special Groups

(1) Gastrointestinal sensitive individuals: It is recommended to take it after meals to reduce gastrointestinal irritation.

(2) People with swallowing difficulties: can open the capsule and mix it with soft food for consumption.

(3) When using combination therapy: attention should be paid to the interaction with other anti-tumor drugs.

4. Administration time management

(1) Omission treatment: If it exceeds 3 hours, there is no need to take it again. Next time, the medication will be given according to the original plan.

(2) Time adjustment: Maintain a 12 hour interval to avoid dose accumulation.

(3) Long term management: It is recommended to set a fixed medication time to improve compliance.

5. Convenience of use

(1) The dosing regimen is simple: take orally twice a day, without the need to adjust the dosage based on body weight.

(2) Stable bioavailability: Food has no significant effect on drug absorption, making medication more convenient for patients.

6 Precautions

(1) Drug resistance monitoring: Attention should be paid to the drug resistance caused by BTKC481S mutation, and regular ctDNA testing is recommended.

(2) Special population medication: Patients with severe liver function impairment need to reduce their dosage, and it is prohibited during pregnancy.